drugset
drugset / Trial / NCT04073550

Study of Anlotinib Hydrochloride Capsule in Subjects With Small Cell Lung Cancer

NCT04073550 ↗

Phase 3 Unknown 184 enrolled Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

Anlotinib hydrochloride is a multi-targeted receptor tyrosine kinase inhibitor that targets angiogenesis-related kinases such as VEGFR1/2/3, FGFR1/2/3, and other tumor-associated kinases involved in cell proliferation such as PDGFRα/β, c-Kit, and Ret have significant inhibitory activities.

Timeline

Start
2019-10-31
Primary completion
2021-07-31
Completion
2022-07-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Catequentinib Small molecule — Oral
Background Topotecan Small molecule 1.5 mg/m2 Intravenous

Indications

small cell lung carcinoma